Author

K. Kobiyama

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Organism:virus· 2 Assay:imaging· 1 Organism:non-human primate· 1

Frequent Co-Authors

K. J. Ishii· 5 shared J. Ito· 3 shared J. Zahradnik· 3 shared K. Uriu· 3 shared The Genotype to Phenotype Japan (G2P-Japan) Consortium· 3 shared Y. Kosugi· 3 shared B. Temizoz· 2 shared D. Yamasoba· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

K. J. Ishii

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Virological characteristics of the SARS-CoV-2 JN.1 variant

Y. Kaku, K. Okumura, M. Padilla-Blanco, Y. Kosugi, K. Uriu, A. A. Hinay, L. Chen, A. Plianchaisuk, K. Kobiyama, K. J. Ishii, The Genotype to Phenotype Japan (G2P-Japan) Consortium, J. Zahradnik, J. Ito, K. Sato

This study investigates the virological properties of the SARS-CoV-2 JN.1 variant, focusing on its mutations and potential immune evasion capabilities.

bioRxiv · Dec 8, 2023Microbiology

5,6-dimethylxanthenone-4-acetic acid (DMXAA), a Partial STING Agonist, Competes for Human STING Activation

B. Temizoz, T. Shibahara, K. Hioki, T. Hayashi, K. Kobiyama, M. S. J. Lee, N. Surucu, E. Sag, A. Kumanogoh, M. Yamamoto, M. Gursel, S. Ozen, E. Kuroda, C. Coban, K. J. Ishii

This paper investigates DMXAA's partial STING agonist activity and develops HHMX, a derivative that antagonizes STING-mediated immune responses in both humans and mice.

bioRxiv · Dec 7, 2023 · PreprintImmunology

Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA.2.12.1, BA.4 and BA.5

I. Kimura, D. Yamasoba, T. Tamura, N. Nao, Y. Oda, S. Mitoma, J. Ito, H. Nasser, J. Zahradnik, K. Uriu, S. Fujita, Y. Kosugi, L. Wang, M. Tsuda, M. Kishimoto, , K. Sato

This study analyzes the virological characteristics of SARS-CoV-2 Omicron variants BA.2.12.1, BA.4, and BA.5, finding they have higher reproduction numbers, reduced neutralization by prior immunity, increased replication in lung cells, and greater pathogenicity in hamsters compared to BA.2.

bioRxiv · May 26, 2022Microbiology

Virological characteristics of SARS-CoV-2 BA.2 variant

D. Yamasoba, I. Kimura, H. Nasser, Y. Morioka, N. Nao, J. Ito, K. Uriu, M. Tsuda, J. Zahradnik, K. Shirakawa, R. Suzuki, M. Kishimoto, Y. Kosugi, K. Kobiyama, T. Hara, , Sawa

This study compares the virological characteristics of SARS-CoV-2 BA.2 and BA.1 variants, finding BA.2 has higher transmissibility, different antigenicity, greater replicative capacity, and higher pathogenicity in hamsters.

bioRxiv · Feb 14, 2022Microbiology

Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domain

K. Kobiyama, M. Imai, N. Jounai, M. Nakayama, K. Hioki, K. Iwatsuki-Horimoto, S. Yamayoshi, J. Tsuchida, T. Niwa, T. Suzuki, M. Ito, S. Yamada, T. Watanabe, M. Kiso, H. Negishi, , K. J. Ishii

This study optimizes an LNP-mRNA vaccine targeting SARS-CoV-2 RBD by removing reactogenic materials, improving immunogenicity and protection in macaques.

bioRxiv · Mar 4, 2021 · PreprintImmunology